NCT07169942CompletedPhase 2
Aleniglipron Phase 2 Body Composition Study
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study Evaluating the Effects of Aleniglipron (GSBR-1290) on Body Composition in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2)
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 44 weeks of treatment.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- First submitted
- 20 Aug 2025
- Start date
- 15 Aug 2025
- Primary completion date
- 9 Sept 2026
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Diseases
- Obesity
- NCT number
- NCT07169942
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 71
- From 15 Aug 2025 to the primary completion date, 9 Sept 2026
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous documented diagnosis of diabetes mellitus
- Self-reported change in body weight \>5% within 3 months before Screening
- Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
Other illness
- Have obesity induced by other endocrine disorders (such as Cushing's syndrome, Prader-Willi syndrome, or melanocortin 4 receptor deficiency)
Other
- Have a body weight, height, and/or width that prohibits the ability to obtain accurate measurements according to the DXA study specific manual that allows hemi-scan
Who the study is looking for
- Signed informed consent
- Participants age ≥18 years and \<80 years, with BMI ≥30 kg/m2
- Screening HbA1c \<6.5 %
Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Austin | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| - Coordinator of this site? Confirm its status | City of Saint Peters | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Moncks Corner | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Norman | United States | Unknown status |
| - Coordinator of this site? Confirm its status | North Charleston | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Phoenix | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Richfield | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Wilmington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.